BioNTech is trading 4.6% down at $85.22 in thin pre-market action, as the stock faces pressure from broader macro uncertainty following new U.S. tariffs on major trading partners.
- Recent sessions have shown mild weakness, with the stock slipping below the $90 level on July 24.
- There are no fresh company-specific headlines or rating changes overnight to account for the move.
- The decline appears tied to broader risk-off swings currently affecting growth and biotech sectors.